E-Cadherin Expression Is Inversely Proportional to Tumor Size in Experimental Liver Metastases

2002 ◽  
Vol 106 (1) ◽  
pp. 173-178 ◽  
Author(s):  
Hideaki Karube ◽  
Hideki Masuda ◽  
Yukimoto Ishii ◽  
Tadatoshi Takayama
Keyword(s):  
Liver Metastases ◽  
Tumor Size ◽  
Experimental Liver ◽  
E Cadherin

Blood flow of experimental liver metastases in rat as evaluated by the locally injected 133-Xenon washout

1985 ◽  
Vol 185 (3) ◽  
pp. 207-215 ◽  
Author(s):  
C. Merkel ◽  
P. P. Cagol ◽  
P. P. Da Pian ◽  
M. Bolognesi ◽  
D. Sacerdoti ◽  
...  
Keyword(s):  
Blood Flow ◽  
Liver Metastases ◽  
Experimental Liver ◽  
Xenon Washout

scholarly journals Liver Metastases in Newly Diagnosed Pancreatic Ductal Adenocarcinoma: A Population Based Analysis

2020 ◽  
Author(s):  
Guoyi Wu ◽  
Xiaoben Pan ◽  
Baohua Wang ◽  
Xiaolei Zhu ◽  
Jing Wu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Metastases ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Size ◽  
Cox Regression ◽  
Population Based ◽  
The Body ◽  
Ductal Adenocarcinoma ◽  
Rank Test ◽  
Factors Associated

Abstract Background Estimates of the incidence and prognosis of developing liver metastases at the pancreatic ductal adenocarcinoma (PDAC) diagnosis are lacking.Methods In this study, we analyzed the association of liver metastases and the PDAC patients outcome. The risk factors associated with liver metastases in PDAC patients were analyzed using multivariable logistic regression analysis. The overall survival (OS) was estimated using Kaplan-Meier curves and log-rank test. Cox regression was performed to identify factors associated with OS.Results Patients with primary PDAC in the tail of the pancreas had a higher incidence of liver metastases (62.2%) than those with PDAC in the head (28.6%). Female gender, younger age, primary PDAC in the body or tail of the pancreas, and larger primary PDAC tumor size were positively associated with the occurrence of liver metastases. The median survival of patients with liver metastases was significantly shorter than that of patients without liver metastases. Older age, unmarried status, primary PDAC in the tail of the pancreas, and tumor size ≥4 cm were risk factors for OS in the liver metastases cohort.Conclusions Population-based estimates of the incidence and prognosis of PDAC with liver metastases may help decide whether diffusion-weighted magnetic resonance imaging should be performed in patients with primary PDAC in the tail or body of the pancreas. The location of primary PDAC should be considered during the diagnosis and treatment of primary PDAC.

scholarly journals Differences in E-Cadherin and Syndecan-1 Expression in Different Types of Ameloblastomas

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Ramón G. Carreón-Burciaga ◽  
Rogelio González-González ◽  
Nelly Molina-Frechero ◽  
Sandra López-Verdín ◽  
Vanesa Pereira-Prado ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Adhesion Molecules ◽  
Tumor Size ◽  
Cell Adhesion Molecules ◽  
Strong Association ◽  
Tumor Aggressiveness ◽  
Future Studies ◽  
Unicystic Ameloblastoma ◽  
Different Types ◽  
E Cadherin

Ameloblastomas are a group of benign, locally aggressive, recurrent tumors characterized by their slow and infiltrative growth. E-Cadherin and syndecan-1 are cell adhesion molecules related to the behavior of various tumors, including ameloblastomas. Ninety-nine ameloblastoma samples were studied; the expression of E-cadherin and syndecan-1 were evaluated by immunohistochemistry. E-Cadherin and epithelial syndecan-1 were more highly expressed in intraluminal/luminal unicystic ameloblastoma than in mural unicystic ameloblastoma and solid/multicystic ameloblastoma, whereas the stromal expression of syndecan-1 was higher in mural unicystic ameloblastoma and solid/multicystic ameloblastoma. Synchronicity was observed between E-cadherin and epithelial syndecan-1; the expression was correlated with intensity in all cases. There was a strong association between expression and tumor size and recurrence. The evaluation of the expression of E-cadherin and syndecan-1 are important for determining the potential aggressiveness of ameloblastoma variants. Future studies are required to understand how the expression of these markers is related to tumor aggressiveness.

scholarly journals The Expression of E-Cadherin in Somatotroph Pituitary Adenomas Is Related to Tumor Size, Invasiveness, and Somatostatin Analog Response

2010 ◽  
Vol 31 (2) ◽  
pp. 257-257
Author(s):  
Stine Lyngvi Fougner ◽  
Tove Lekva ◽  
Olivera Casar Borota ◽  
John K. Hald ◽  
Jens Bollerslev ◽  
...  
Keyword(s):  
Tumor Size ◽  
Pituitary Adenomas ◽  
Somatostatin Analog ◽  
E Cadherin

scholarly journals The Expression of E-Cadherin in Somatotroph Pituitary Adenomas Is Related to Tumor Size, Invasiveness, and Somatostatin Analog Response

2010 ◽  
Vol 24 (4) ◽  
pp. 874-875
Author(s):  
Stine Lyngvi Fougner ◽  
Tove Lekva ◽  
Olivera Casar Borota ◽  
John K. Hald ◽  
Jens Bollerslev ◽  
...  
Keyword(s):  
Tumor Size ◽  
Pituitary Adenomas ◽  
Somatostatin Analog ◽  
E Cadherin

Developmental stages in experimental liver metastases: Relation to invasiveness

1994 ◽  
Vol 57 (3) ◽  
pp. 433-439 ◽  
Author(s):  
Koert P. Dingemans ◽  
Marius A. van den Bergh Weerman ◽  
Robert F. Keep ◽  
Pranab K. Das
Keyword(s):  
Liver Metastases ◽  
Developmental Stages ◽  
Experimental Liver

A clinical prognosis model for Asian advanced melanoma patients receiving immunotherapy.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14081-e14081
Author(s):  
Xuan Wang ◽  
Xieqiao Yan ◽  
Zhihong Chi ◽  
Lu Si ◽  
Xinan Sheng ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Metastases ◽  
Tumor Size ◽  
Cox Model ◽  
Univariate Analysis ◽  
Advanced Melanoma ◽  
Braf Mutations ◽  
Clinical Prognosis ◽  
C Statistic ◽  
Melanoma Patients

e14081 Background: Immunotherapy PD-1 inhibitor therapy shows relative lower efficacy in Asia especially in acral and mucosal subtypes. The identification of predictive factors of immunotherapy remains a crucial but unmet clinical need. The objective of this study was to evaluate advanced melanoma patients treated with anti-PD-1 in order to identify risk factors for PFS, OS and develop a prognostic scoring system for immunotherapy. Methods: Patients with unresectable melanoma treated with PD-1 inhibitor enrolled on trials between 2015 and 2017 at Peking University Cancer Center were included. A nomogram to predict survival was developed based on a multivariable Cox model. The predictive performance of the model was assessed according to the C-statistic, Kaplan–Meier curve and calibration plots. Results: The discovery cohort comprised 133 patients with unresectable melanoma. 38.3% acral and 21.8% mucosal melanomas were included, 26.3% with liver metastases, 31.6% with an elevated serum LDH, 20.3% harbored BRAF mutations. The median PFS was 4.8 months, based on the Cox model, four factors were selected for the nomogram and assigned specific scores: tumor metastases number≥3, 1; tumor size≥80 mm,1; LDH level, 1 (higher limit of normal range); liver metastases,1. The model achieved relatively good discrimination and calibration, with a C-statistic of 0⋅804 (Table). BRAF mutations were associated with shorter PFS in univariate analysis but not in multivariate analysis. Subtypes were also not related to PFS in this cohort. The median OS was 22.8 months. Univariate analysis identified eight factors were associated with significantly worse OS among 21 factors ( BRAF and subtype included, which not found as risk factors). Based on the Cox model, five factors were selected for the nomogram and assigned specific scores: ECOG > 1, 0.6; Hemoglobin < 120g/ml,0.6; tumor size≥80 mm,1.4; LDH level, 0.5; liver metastases, 1. C-statistic was 0⋅85, with extremely strong predictability (Table). The overall survival rate for patients with a higher score was significantly worse than lower cohort (Score: < 0.6 vs. 1-2 vs. 2-4.1; OS: not reached vs. not reached vs. 8.3m; P < 0⋅001). Conclusions: The nomogram facilitates personalized assessment of prognosis for Asian patients with advanced melanoma with PD-1 inhibitor. [Table: see text]

Immediate post-thermal ablation biopsy of colorectal liver metastases to predict oncologic outcomes.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4602-4602
Author(s):  
Nikiforos Vasiniotis Kamarinos ◽  
Efsevia Vakiani ◽  
Mithat Gonen ◽  
Nancy E. Kemeny ◽  
Anne M. Covey ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Tumor Cells ◽  
Tumor Size ◽  
Thermal Ablation ◽  
Colorectal Liver Metastases ◽  
Univariate Analysis ◽  
Contrast Material ◽  
Maximum Diameter ◽  
Minimal Risk ◽  
Viable Tumor

4602 Background: Thermal ablation (TA) is used as a local cure for selected colorectal liver metastases (CLM) with minimal risk. A critical limitation of TA has been early local tumor progression (LTP). The goal of this study is to establish the role of ablation zone (AZ) biopsy in predicting LTP. Methods: This institutional review board-approved prospective study included patients with CLM of 5cm or less in maximum diameter, with confined liver disease or stable, limited extrahepatic disease. Both radiofrequency(RF) and microwave(MW) ablation modalities were used. A biopsy of the center and margin of the AZ was performed immediately after ablation. The applicators were also examined for the presence of viable tumor cells. All samples containing morphologically identified tumor cells were further interrogated with immunohistochemistry to determine the proliferative and viability potential of the detected tumor cells. Ablation margin size was evaluated on the first CT scan performed 4–8 weeks after ablation and was confirmed by 3D assessment with Ablation Confirmation Software (Neuwave™). Variables were evaluated as predictors of time to LTP with the competing-risks model (uni- and multivariate analyses). Results: Between November 2009 and February 2019, 102 patients with 182 CLMs were enrolled. Mean tumor size was 2.0 cm (range, 0.6–4.8 cm). MW was used in 95/182 (52%) tumors and RF in 87/182 (48%). Median follow-up was 19 months. Technical effectiveness was evident in 178/182 (97%) ablated tumors on the first contrast material–enhanced CT at 4–8-weeks post-ablation. The cumulative incidence of LTP at 12 months was 19% (95% confidence interval [CI]: 14, 27). Samples from 64 (35%) of the 178 technically successful cases contained viable tumor. At univariate analysis, tumor size, minimal margin size, and biopsy results were significant in predicting LTP. In a multivariate model, margin size of less than 5 mm (P < .001; hazard ratio [HR], 4.3), and positive biopsy results (P = .02; HR, 1.8) remained significant. LTP within 12 months after TA was noted in 3% (95% CI: 1, 6) of tumor-negative biopsy CLMs with margins of at least 5 mm. Conclusions: Biopsy and pathologic examination of the AZ predicts LTP regardless of TA modality used. This can optimize ablation as a potential local cure for patients with limited CLM.

Sign in / Sign up

Export Citation Format

Share Document